Skip to content
CancerIndex

Publication

Early Serum Free Light Chain Response in Newly Diagnosed Multiple Myeloma: Documented Earlier Than MRD and Complementary in Prognosis.

Yubiao Pan, Yue Wang, Yaqin Xiong, Panpan Li, Chenqi Yu, Peng Liu

Hematological oncologySep 1, 2026PMID 42549699doi:10.1002/hon.70234 PMC13435342Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 17, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260917-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Minimal residual disease (MRD) is the standard for deep response assessment in multiple myeloma but requires bone marrow sampling. Whether early serum free light chain (sFLC) response provides independent prognostic information in real-world, predominantly non-transplant patients remains unclear.…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.